Dow Jones received a payment from EQS/DGAP to publish this press release.
goetzpartners securities Limited
4SC AG (VSC-DE): Orphan to best-in-class: HDACi come of age
11-Dec-2017 / 09:38 GMT/BST
*This equity research note was formally published on 11th December 2017 at
5.00am.*
*goetzpartners securities Limited equity research initiation review on 4SC AG
(VSC-DE): Orphan to best-in-class: HDACi come of age*
*Report type: Initiation Note *
*Recommendation: OUTPERFORM*
*Target price: EUR7.50*
*Current price (as at cob 8th December 2017): EUR5.05*
With a pipeline based on sound proof-of-principle, 4SC is building an
independent strategy focussed on orphan drugs with best-in-class blockbusters
exploited through major partners. The company's lead product resminostat is in
a pivotal trial as a much-needed maintenance therapy in the orphan CTCL
(Cutaneous T-Cell Lymphoma). Class I HDACi (Histone Deacetylase inhibitors)
are showing real promise in combination with the new wave of
immuno-therapeutics. Entering phase II in combination with an approved
checkpoint inhibitor in melanoma, the safety and efficacy of the Class I HDACi
4SC-202 provide the hallmarks of a best-in-class blockbuster as well as
providing a snug fit into the company's orphan strategy. We initiate with an
OUTPERFORM recommendation and a fair value of EUR7.50 / share potentially
rising to over EUR10 / share with expected newsflow from the pipeline as well
as non-core assets over the next 6 to 12 months.
*Proof-of-principle* - Although HDAC inhibitors ("HDACi") have frequently
disappointed, a number of drugs are now approved or moving through the clinic.
Their potential in certain blood cancers and particularly as combinations to
boost the efficacy of the current wave of immunotherapies is increasingly
evident.
*Filling a need in CTCL* - With patients frequently subjected to numerous
sequential cycles of various short acting therapies, there is an urgent need
for an effective maintenance therapy in advanced CTCL. Evidence supports the
use of resminostat with the drug now in one of the first and largest
placebo-controlled pivotal trials in CTCL; reporting 2019.
*Potential best-in-class* - Sound science and clinical data point to the
potential of Class I HDACi to boost and extend the efficacy of the current
wave of cancer immunotherapies. Entering phase II proof-of-concept in melanoma
(SENSITIZE), 4SC-202's superior safety and efficacy mark it out as potential
best-in-class for combination with immune checkpoint inhibitors in large
blockbuster indications as well as part of 4SC's orphan skin cancer portfolio.
*Orphans provide independence* - With smaller more manageable clinical trials
orphan indications provide a realistic opportunity for 4SC to develop and
commercialise an independent self-sustaining portfolio of therapeutics
targeted at dermatology.
*Funded to inflection -* The company is well funded with EUR41m raised
mid-2017. This plus potential payments from partnered non-core assets (not
included in our forecasts) should see the company funded through 2020. With
strong newsflow from the in-house orphan portfolio, the prospect of large
partners for 4SC-202 combinations, we see upside for the stock. Our risk
adjusted DCF indicates a valuation and target price of EUR7.50 / share
potentially rising to over EUR10 on positive news. We initiate with an
OUTPERFORM recommendation.
Click here for full PDF version [1]
goetzpartners Corporate Research | Research Team
Dr. Chris Redhead | Analyst
goetzpartners Corporate Sponsored Research
goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.
T +44 (0) 203 859 7725 | healthcareresearch@goetzpartners.com /
chris.redhead@goetzpartners.com
www.goetzpartnerssecurities.com [2]
Registered in England No. 04684144.
Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.
To be added, or to change your subscriptions or to be removed / unsubscribed
entirely from our CRM, please e-mail: ResearchProduction@goetzpartners.com
This research report is intended for use only by persons who qualify as
professional investors or eligible counterparties (institutional investors) in
the applicable jurisdiction, and not by any private individuals or other
persons who qualify as retail clients.
This communication (including any links and or attachments) from goetzpartners
securities Limited ("GPSL") is confidential and may contain information which
is proprietary, privileged or otherwise legally protected against unauthorised
use or disclosure. If you receive this communication in error or are not the
intended recipient of this communication, please delete and destroy all copies
in your possession, notify the sender that you have received this
communication, and note that any review or dissemination of, or the taking of
any action in reliance on this communication is expressly prohibited. GPSL
shall not be liable for the improper or incomplete transmission of the
information contained in this communication nor for any delay in its receipt
or damage to your system. GPSL does not guarantee that the integrity of this
communication has been maintained nor that this communication is free of
viruses, interceptions or interference and makes no warranties in relation to
these matters. This is not an offer or a solicitation to buy or sell
securities or investment products, or an official confirmation. GPSL [3] is
authorised and regulated by the Financial Conduct Authority of the United
Kingdom (Firm Reference Number: 225563).
About GPSL [2]*:* goetzpartners securities Limited is a member of the
goetzpartners group and a leading true pan European investment bank and
research firm. We bring together a wide range of expertise, insights and
innovations to advance the interests of our clients around the world. The fast
changing environment brings challenges for businesses and investors. Research
innovation, digital transformation and disruptive business ideas reshuffle the
corporate world in a yet unexperienced pace. Our sector knowledge and our
global footprint bring together deep understanding of the industry, corporate
intelligence and a wide network of top decision makers.
GPSL publishes both non-independent (corporate sponsored) and investment
research.
Click on the following hyperlink for our Research Library: GPSL Equity
Research Library [4]
GPSL equity research publications are also available and accessible on the
following aggregators (for Institutional Use Only): AlphaSense, Bloomberg
(GOET), Capital IQ, EQS, FACTSET, RNS Reach and Thomson Reuters.
If you cannot click on the above hyperlink please copy the below link and
paste it into your browser for the full pdf version of the equity research
report.
https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=719f004b-9dd5-448f-b
203-f7a316653acd&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=library
View [5]
Dissemination of a FINANCIAL NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
637539 11-Dec-2017
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=624a4b3e18a0a65c3025bda81cbefd4d&application_id=637539&site_id=vwd&application_name=news
2: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=750ca54579c5d5447638f7f35718f4d1&application_id=637539&site_id=vwd&application_name=news
3: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ba4d174d6cc17a15461e9920a97cb6e6&application_id=637539&site_id=vwd&application_name=news
4: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a8a38ea79831272865b5aae2e3600818&application_id=637539&site_id=vwd&application_name=news
5: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=8bca146e9798eff83da02c49aea00a92&application_id=637539&site_id=vwd&application_name=news
(END) Dow Jones Newswires
December 11, 2017 04:38 ET (09:38 GMT)
